Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common stock, $0.0001 par value
-
Shares outstanding
-
49.9M
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
8.47M
-
Shares change
-
+5.52M
-
Total reported value, excl. options
-
$46.2M
-
Value change
-
+$30.1M
-
Number of buys
-
36
-
Number of sells
-
-10
-
Price
-
$5.45
Significant Holders of TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) as of Q2 2025
54 filings reported holding TLSI - TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value as of Q2 2025.
TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.47M shares
of 49.9M outstanding shares and own 16.98% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (2M shares), AWM Investment Company, Inc. (1.25M shares), GILDER GAGNON HOWE & CO LLC (1.09M shares), VANGUARD GROUP INC (814K shares), Wealthcare Advisory Partners LLC (644K shares), BlackRock, Inc. (622K shares), Alyeska Investment Group, L.P. (558K shares), GEODE CAPITAL MANAGEMENT, LLC (455K shares), BANK OF AMERICA CORP /DE/ (189K shares), and NORTHERN TRUST CORP (126K shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.